26 Aug 2008 15:02
FOR PUBLICATION IN THE UNITED KINGDOM ONLY. NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, OR INTO ANY OTHER JURISDICTION WHERE THE EXTENSION OR AVAILABILITY OF THE PLACING AND OPEN OFFER WOULD BREACH ANY APPLICABLE LAW.
PuriCore plc
("PuriCore" or the "Company")
Result of General Meeting
Malvern, Pennsylvania, and Stafford, UK, 26 August 2008 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green products that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment announces that at the General Meeting of the Company held today all of the resolutions were duly passed by Shareholders. The proxy figures for the resolutions will available shortly on the company's investor website at http://investor.puricore.com.
Application has been made for the 44,937,890 Placing Shares and the 18,672,946 Open Offer Shares to be admitted to the Official List and to trading on the London Stock Exchange's main market for listed securities. It is expected that Admission will become effective and dealings will commence at 08.00 am on 27 August 2008.
Enquiries:
| PuriCore | +1 484 321 2700 |
| Greg Bosch, CEO | |
| Keith A. Goldan, CFO |
| Nomura Code Securities Limited | +44 (0) 20 7776 1200 |
| Phil Walker |
| Financial Dynamics | +44 (0) 20 7831 3113 |
| Ben Brewerton | |
| Susan Quigley |
About PuriCore
PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore targets markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, and wound therapy. The Company's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores, simply from water, common salt, and electricity. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of M. tuberculosis, MRSA, E.coli, Norovirus, H5N1 Avian Influenza, HIV, Salmonella, Polio Virus, Helicobater pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.
To subscribe to our investor news alerts, visit investor.puricore.com.
Nomura Code Securities Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting for the Company as sponsor, financial adviser, broker and underwriter in connection with the Placing and the Open Offer and not for any other person and will not be responsible to any other person for providing the protections afforded to its customers or for providing advice in relation to the Placing and the Open Offer, the contents of the prospectus and, if relevant, the accompanying documents or any arrangements referred to therein.